

RESEARCH ARTICLE OPEN ACCESS

The Clinical Impact of Somatic Copy Number Variations in Patients With Stage IV Wilms Tumor Enrolled in the SIOP 2001 Trial and Study

Nils Welter¹  | Reem Al-Saadi^{2,3} | Robinson Gravier-Dumonceanu⁴ | Rhoikos Furtwängler⁵ | Norbert Graf¹ | Jenny Wegert⁶ | Manfred Gessler⁶ | Richard D. Williams^{2,7} | Kathy Pritchard-Jones²  | Aurore Coulomb-L'Hermine⁸ | Marry M. van den Heuvel-Eibrink⁹ | Arnaud C. Verschuur¹⁰ 

¹Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany | ²Developmental Biology and Cancer Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK | ³Department of Histopathology, Great Ormond Street Hospital for Children, London, UK | ⁴APHM, Hop Timone, BioSTIC, Biostatistique et Technologies de l'Information et de la Communication, Marseille, France | ⁵Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital University Hospital, Bern, Switzerland | ⁶Developmental Biochemistry and Comprehensive Cancer Centre Mainfranken, Theodor-Boveri-Institute/Biocenter, University of Würzburg, Würzburg, Germany | ⁷Section of Genetics and Genomics, Faculty of Medicine, Imperial College London, London, UK | ⁸AP-HP, Department of Pathology, Armand Trousseau Hospital, Paris, France | ⁹Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands | ¹⁰Department of Pediatric Haematology-Oncology, La Timone Children's Hospital, AP-HM, Marseille, France

Correspondence: Nils Welter (nils.welter@uks.eu)

Received: 17 July 2024 | **Revised:** 16 January 2025 | **Accepted:** 22 January 2025

Keywords: copy number variations | outcome | preoperative chemotherapy | stage IV | Wilms tumor

ABSTRACT

Background: Recent research elucidated the prognostic significance of molecular biology in Wilms tumor (WT) by linking somatic genomic variants (such as gain of chromosome 1q) to unfavorable patient outcomes. This analysis describes the clinical impact of copy number variations (CNV) in tumor samples of WT patients with stage IV disease.

Methods: Tumor samples of 55 WT patients with stage IV disease from the United Kingdom, France, and Germany enrolled in the SIOP 2001 study and treated with preoperative chemotherapy (pCHT) were examined for their CNVs of chromosome 1q and other regions of interest using multiplex ligation-dependent probe amplification (MLPA). The identified CNV were analyzed regarding their prognostic impact.

Results: Chromosome 1q gain (1q+) and *TP53* loss occurred in 38.2% and 16.4% of tumors and were associated with older patient age at diagnosis (median [months]: 65 and 64 vs. 49 each, $p = 0.03$ and 0.02 , respectively) and poorer 5-year event-free survival (40.0% and 11.1% vs. 67.7% and 82.6%, $p = 0.04$ and <0.01 , respectively) compared to their specific control group of tumors without the respective CNV. In patients with pulmonary-only metastasis, 1q+ was an adverse prognostic marker irrespective of remission status after pCHT with or without metastasectomy. A simultaneous *MYCN* gain occurred more frequently in tumors with 1q+ than in tumors without 1q+ ($p = 0.03$). *TP53* loss was linked to high-risk histology and inferior 5-year overall survival ($p < 0.001$).

Abbreviations: CNV, copy number variations; COG, Children's Oncology Group; CR, complete remission; CT, computed tomography; DA, diffuse anaplasia; EFS, event-free survival; HR, high risk; IR, intermediate risk; LOH, loss of heterozygosity; OS, overall survival; pCHT, preoperative chemotherapy; pRT, pulmonary RT; RT, radiation therapy; SIOP-RTSG, International Society of Pediatric Oncology Renal Tumor Study Group; TV, tumor volume; WT, Wilms tumor.

Nils Welter and Reem Al-Saadi are both co-first authors.

Previous presentation: Partly presented as a poster at the SIOP Congress, Lyon, France, October 23–26, 2019. Verschuur et al. Biomarker Candidates of Outcome in Children with Stage IV Nephroblastoma in the SIOP 2001 Study, <https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.2798>.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Pediatric Blood & Cancer* published by Wiley Periodicals LLC.

Conclusions: We confirm the prognostic relevance of 1q+ and *TP53* loss in stage IV WTs and emphasize their potential utility for future treatment stratification.

1 | Introduction

Wilms tumor (WT) is the most common kidney tumor in children younger than 15 years with a prevalence of over 85% [1, 2]. At least 12% of WT patients in Europe present with distant metastasis [3–7]. The most common metastatic site is the lung (85%–95%), followed by the liver (approximately 15%) and other sites (<5%) including abdominal, bone, and brain metastasis [3, 4, 8]. Bone metastases are present in only 0.4% of WT patients and are associated with poor prognosis [9].

The overall survival (OS) for WT of all stages is approximately 90% for newly diagnosed cases [7, 10, 11] and 15%–79% for patients who relapse, with those with high-risk (HR) histology at relapse doing significantly worse [12–16]. The prognosis of metastatic patients treated with preoperative chemotherapy (pCHT) is less favorable with a 5-year OS of 82%–83% compared to patients with localized WT (5-year OS of 90%–98% depending on local stage), although stage IV patients receive more intensive treatment compared to patients with localized disease [3, 17, 18].

WT is treated according to either the SIOP-RTSG (International Society of Pediatric Oncology Renal Tumor Study Group) or the North American Children's Oncology Group (COG) protocols. The SIOP-RTSG has been following the approach of administering 4 weeks of pCHT as standard of care for localized renal tumors since the completion of the SIOP-9 study in 1991 [5, 19]. Metastatic patients initially receive 6 weeks of pCHT, followed by surgery. Postoperative treatment is based on histology, local abdominal stage, and postoperative remission status of metastases [5, 11, 13, 20].

In the SIOP-RTSG protocols, age, histological subtypes, tumor stage, preoperative tumor volume (TV), and for stage IV patients, the metastatic remission status after pCHT are among the relevant prognostic factors for treatment stratification of WT [3, 11, 17, 21–26]. Molecular markers, including copy number variations (CNV), have not yet been implemented for treatment stratification in the SIOP-RTSG protocols [13]. Chagtai et al. showed that 28% of 586 WT (stage I–IV) patients treated with pCHT harbored 1q+, and these were associated with an approximately two-fold higher risk of relapse [27]. In addition, further genomic CNVs with adverse prognostic impact have been identified in WT, notably *TP53* loss at 17p, *MYCN* gain and loss of 1p, and loss of 16q [27–32]. Besides CNVs, driver mutations in several other genes involved in WT tumorigenesis such as *WT1*, *CTNBL1*, *TP53*, *MYCN*, *SIX1/2*, *DROSHA*, and *DGCR8* are potentially associated with outcome [33–36].

In this study, we investigated in detail the prognostic significance of genomic CNVs in patients with stage IV WT, as a subgroup of the patients described by Chagtai et al. [27].

2 | Materials and Methods

2.1 | Patients and Cohorts

Patients were eligible for study, if (i) they were registered in the SIOP 2001 study after informed consent; (ii) enrolled in the UK, France, or Germany; (iii) diagnosed with stage IV WT; and (iv) had molecular analysis by multiplex ligation-dependent probe amplification (MLPA) of a fresh-frozen tumor sample as performed and reported by Chagtai et al. [27]. Metastatic disease was defined according to SIOP stage IV criteria [5]. Pulmonary metastasis had to be detectable on the chest x-ray, and patients with computed tomography (CT)-only nodules as defined in Smets et al. were not eligible for the analysis, as these constitute a separate subgroup with a different outcome compared to patients with overt metastasis [37, 38].

2.2 | Diagnostic and Therapeutic Guidelines of the SIOP 2001 Study

Once a WT was suspected, patients routinely underwent abdominal cross-sectional imaging (MRI or CT) and conventional chest x-ray ± chest CT for pulmonary staging to determine the extent of disease. Initial and preoperative TVs were assessed by imaging (MRI, CT, or ultrasound) and calculated using the ellipsoid formula ($TV = \text{Length} \times \text{Height} \times \text{Depth} \times 0.523$).

The patients were treated according to the international SIOP treatment guidelines with vincristine (V), actinomycin (A), and doxorubicin (D) for 6 weeks, followed by surgery as per guidelines [5, 6]. After pCHT and tumor-nephrectomy with lymph node sampling, the histologic subtype and local staging were determined according to the SIOP-RTSG histology classification for renal tumors [39]. Moreover, the remission status of metastases was assessed radiologically by CT with two outcomes: metastases (i) absent or completely excised (complete remission [CR]); or (ii) incompletely excised or inoperable (non-CR). Depending on these parameters, the patients of group (i) continued with AVD as standard postoperative treatment, while group (ii) and patients with HR histology received intensified four-drug regimen with VP-16 (V), carboplatin (C), cyclophosphamide (C), and doxorubicin (D). Patients in non-CR usually underwent pulmonary biopsy. If no viable tumor cells in a representative number of metastasis were identified, no treatment intensification was applied [6].

Patients with inoperable metastasis at Week 6 after tumor nephrectomy and/or HR histology received radiotherapy (RT) to the metastatic site. In case of pulmonary metastasis, whole lung RT has been recommended in the protocol [3, 5], whilst all patients with local stage III intermediate-risk (IR) or HR

tumors and local stage II diffuse anaplasia (DA) received flank RT.

2.3 | Statistics and Data Analysis of the Stage IV Cohort

The data were extracted from the SIOP 2001 database, completed by queries to the local sites for missing clinical data and imported in IBM SPSS statistics version 29. Statistical analyses were performed on the clinical and tumor-related variables of interest. Subsequently, comparisons were performed using Pearson's chi-square test or Fisher's exact test depending on expected values of greater than 5 or ≤ 5 for categorical variables, respectively, and Wilcoxon rank-sum test for non-normally distributed variables to determine significant associations between the respective CNVs and between CNVs and the clinical parameters. We classified the tumors into those with the respective CNV of interest (1q+, *TP53* loss, *MYCN* gain) and those in which the respective CNV was absent (other status). For survival and time-to-event analysis, Kaplan–Meier lifetables were generated, and differences between survival curves were tested using log rank test. Two-sided *p*-values below 0.05 were considered statistically significant.

3 | Results

3.1 | Patient and Tumor Characteristics

In the SIOP 2001 study, 373 patients with stage IV WT from the United Kingdom (110), France (118), and Germany (145) were enrolled, out of which 65 patients had fresh frozen samples available for this study. Ten patients with CT-only nodules and/or incomplete data were excluded resulting in 55 patients, including 15 patients from the United Kingdom, 22 from France, and 18 from Germany. The median age of these patients was 54 months (interquartile range [IQR]: 35–65 months) and 50.9% were males (Table 1). Ninety-two percent of patients received the preoperative standard-of-care AVD treatment for 6 weeks, and 5.6% received only 4 weeks of AV (physician's choice) (Table 1). A median TV reduction of 78% (range: 57–86) was observed after pCHT, from a median initial TV of 720 mL (IQR: 504–985 mL) to a median TV at surgery of 175 mL (IQR: 76–348). IR and HR histology represented 80.0% and 20.0%, respectively. All patients with HR histology had DA. The local stage distribution was 25.5%, 20.0%, and 54.5% for abdominal stage I, II, and III, respectively. Postoperative CHT consisted of 55.8% AVD and 36.5% for the VCCD HR regimen. Only 7.7% of patients had a different kind of treatment (physician's choice) (Table 1).

Data on RT were available in 50 patients, of whom 33 (66.0%) underwent RT. Fourteen (28.0%) received local RT, either to the flank or to the whole abdomen. Nineteen (38.0%) patients were irradiated to the metastatic site, seven of them received only pulmonary RT (pRT), nine pRT in combination with local RT to the flank or abdomen, and three patients received pRT as well as RT to one other site with or without liver RT. Seventeen patients (34.0%) were treated with CHT and surgery only, without RT.

Three of the 22 patients with metastatic CR and one of 14 patients with non-CR and available data on RT received pRT.

Twenty-two patients out of 55 had an event, and 40 patients were still alive after an average follow-up period of 5 years, resulting in a 5-year event-free survival (EFS) of 60.0% and OS of 72.7% (Table 1, Figure 1).

3.2 | Metastasis

Forty of 55 patients (72.7%) had pulmonary-only metastasis. Nine patients had pulmonary metastasis and at an additional site (four liver, one bone, two extra-abdominal, one other site, one abdomen), three patients had extensive metastasis in three or more sites including lung and liver, two patients had isolated locoregional peritoneal spread, and one patient isolated liver metastasis (Table 2).

Twenty-four of 52 patients with available data achieved a metastatic CR after pCHT and surgery, and 28 (53.8%) had a non-CR (remission status was not available for three). The remission rate varied according to the site of metastasis (Table 2). Twenty-two out of 39 patients with pulmonary-only metastasis achieved remission after pCHT and surgery, whereas only one out of eight patients with pulmonary metastasis and metastasis at one additional site achieved CR (Table 2).

3.3 | Molecular Genetics and Biomarker

All patients had samples examined by MLPA for the previously selected loci; 1q+ was the commonest CNV, found in 21 (38.2%) patient samples, followed by *MYCN* gain ($n = 10$, 18.2%) and *TP53* loss ($n = 9$, 16.4%). Loss of 16q, loss of 1p, and simultaneous loss of 1p and 16q were present in eight (14.5%), five (9.1%), and one patient (1.8%), respectively (Tables 1 and 3). Loss of *WT1* and *WTX* were detected in two and one patients, respectively. Tumors harboring 1q+ were more likely to have additional CNVs than tumors with 1q other status ($p = 0.03$). In particular, *MYCN* gain occurred significantly more frequently, if 1q+ was present ($p = 0.03$) (Table 3).

1q+ and *TP53* loss were analyzed regarding their respective association with patient characteristics at diagnosis, TV, histology, and outcome. Patients with tumors harboring 1q+ or *TP53* loss were significantly older at diagnosis than patients with 1q and *TP53* other status ($p = 0.03$ and 0.02, respectively).

Tumors with 1q+ showed a significantly worse 5-year EFS (EFS: 42.9% for patients with 1q+ tumors vs. 70.6% 1q other status, $p = 0.04$), which did however not translate in a significant inferior OS (Table 1, Figure 1, $p = 0.19$). Of the 18 patients with tumors harboring 1q+, pulmonary metastasis ($n = 15$ with pulmonary-only metastasis) and complete data on RT, 13 had no pRT (seven events) and five had pRT (two events).

Tumors with *TP53* loss showed no significant difference in pCHT-induced volume reduction compared to tumors with *TP53* other status (Table 4), but they were associated with a significantly higher proportion of HR histology ($p < 0.01$) and poorer EFS and OS ($p < 0.01$ for both) than tumors with *TP53* other status (Table 4, Figure 1).

TABLE 1 | Overview.

Age [months], (n = 55)				Sex	N	%	Tumor site	N	%	
Patients	Median (IQR)	54 (35–65)	Males	28	50.9		Right	27	49.1	
			Females	27	49.1		Left	28	50.9	
At diagnosis [mL] (n = 50)				At surgery [mL] (N = 46)		Reduction [%] (N = 46)				
TV	Median (IQR)	720 (504–985)		Median (IQR)	175 (76–348)		Median (IQR)	78 (57–86)		
Risk group		N	%	Stage	N	%				
Histology	LR	0	0.0	I	14	25.5				
	IR	44	80.0	II	11	20.0				
	HR	11	20.0	III	30	54.5				
Preop (n = 54)		N	%	Post-op (n = 52)	N	%	Remission of metastasis after surgery (n = 51)			
CHT	AV	3	5.6	AVD	29	55.8	CR with CHT	20	38.5	
	AVD ^a	50	92.6	VCCD	19	36.5	CR with CHT+OP	4	7.7	
	Other	1	1.9	Other	4	7.7	Non-CR	28	53.8	
	NA	1		NA	3		NA	3		
1q status		N	%	TP53	N	%	MYCN	N	%	
Biology	Gain	21	38.2	Loss	9	16.4	Gain	10	18.2	
	Normal	34	61.8	Other	46	83.6	Normal	45	81.8	
OS		N	%	EFS	N	%	Tumor specific survival		N	%
Outcome	Alive	40	72.7	Event free	33	60.0	Alive/Death from other cause	41	74.5	
	Dead	15	27.3	Event	22	40.0	Died of cancer	14	25.5	

Abbreviations: CHT, chemotherapy; CR, complete remission; EFS, event-free survival; HR, high risk; IR, intermediate risk; N, absolute number of patients with available data; NA, not available; OS, overall survival; TV, tumor volume.

^aModified AVD in N = 25 patients meaning a dose reduction for any of the three compounds (physician's choice)

No influence of 1q+ and TP53 loss on the remission status after pCHT and surgery was identified. However, regarding TP53, only 22.2% of patients with TP53 loss achieved CR compared to 51.2% with TP53 other status ($p = 0.15$, Table 4).

Five-year EFS and OS of patients with pulmonary-only metastasis in non-CR after 6 weeks of pCHT±metastatectomy, were significantly worse if 1q+ was present (28.6% [$p = 0.04$] and 38.1% [$p = 0.03$], respectively). For patients in CR, no significant differences were observed for EFS and OS depending on 1q status (Figure 2). We further investigated the prognostic impact of pRT in patients with pulmonary-only metastasis and 1q+. Out of 15 patients with pulmonary-only metastasis and 1q+, three received pRT. No significant differences in 5-year EFS (pRT given: 66.7%, no pRT given: 66.7%, $p = 0.56$) and 5-year OS (66.7% for both pRT given, and no pRT given: 66.7%, $p = 0.85$) were obtained.

4 | Discussion

It has been established that genomic CNVs such as 1q+, TP53 loss, and MYCN gain may affect the malignant potential, response to treatment, and ultimately the prognosis of WT [27, 28, 31, 40–42]. Loss of 16q was also related to an increased risk of relapse and death in the UKW 1–3 trial [32]. The COG identified loss of heterozygosity (LOH) on chromosomes 1p and 16q in WT as an adverse prognostic marker, and is currently used for treatment stratification [13, 40, 43–47]. 1q+ has been identified as a prognostic marker in various series [27, 31, 40, 43, 46–48].

Stage IV WT patients have a worse outcome compared to patients with localized disease, and for those with HR histology the outcome is dismal [6]. Although targeted treatment options and novel agents are currently lacking for WT, these patients could benefit from histology or molecular risk-tailored treatment




FIGURE 1 | Prognostic impact of the respective copy number variations (CNVs). A and B: all patients ($n = 55$).

TABLE 2 | Site of metastasis and metastatic response.

	Lung only n (%)	Lung + 1 other site n (%)	Lung, liver + other site n (%)	Abdomen n (%)	Liver n (%)	Total n (%)
All						
All	40 (72.7)	9 (16.4)	3 (5.5)	2 (3.6)	1 (1.8)	55 (100)
CR with CHT	18 (46.2)	1 (12.5)			1 (100)	20 (38.5)
CR with surgery	4 (10.3)	0 (0.0)				4 (7.7)
Non-CR	17 (43.6)	7 (87.5)	3 (100)	1 (100)		28 (53.8)
NA	1	1		1		3
1q						
Gain	17 (81.0)	4 (19.0)	0 (0.0)	0 (0.0)	0 (0.0)	21 (100)
CR with CHT	9 (52.9)	1 (25.0)				10 (47.6)
CR with surgery	1 (5.9)	0 (0.0)				1 (4.8)
Non-CR	7 (41.2)	3 (75.0)				10 (47.6)
No gain	23 (67.6)	5 (14.7)	3 (8.8)	2 (5.9)	1 (2.9)	34 (100)
CR with CHT	9 (40.9)				1 (100)	10 (32.3)
CR with surgery	3 (13.6)					3 (9.7)
Non-CR	10 (45.5)	4 (100)	3 (100)	1 (100)		18 (58.1)
NA	1	1		1		3
TP53						
Loss	6 (66.7)	2 (22.2)	0 (0.0)	1 (11.1)	0 (0.0)	9 (100)
CR with CHT	1 (16.7)					1 (11.1)
CR with surgery	1 (16.7)					1 (11.1)
Non-CR	4 (66.7)	2 (100)		1 (100)		7 (77.8)
No loss	34 (73.9)	7 (15.2)	3 (6.5)	1 (2.2)	1 (2.2)	46 (100)
CR with CHT	17 (51.5)	1 (16.7)			1 (100)	19 (44.2)
CR with surgery	3 (9.1)					3 (7.0)
Non-CR	13 (39.4)	5 (83.3)	3 (100)			21 (48.8)
NA	1	1		1 (100)		3
1q and/or TP53						
No alteration	20 (71.4)	4 (14.3)	2 (7.1)	1 (3.6)	1 (3.6)	28 (100)
CR with CHT	9 (47.4)				1 (100)	10 (40.0)
CR with surgery	2 (10.5)					2 (8.0)
Non-CR	8 (42.1)	3 (100)	2 (100)			13 (52.0)
NA	1	1		1		3

Abbreviations: CHT, chemotherapy; CR, complete remission; NA, not available.

[6, 12, 14, 17, 49]. The aim of our study was to determine the clinical and prognostic impact of CNVs in a subgroup of preoperatively treated stage IV WT patients and to assess their suitability for future risk stratification.

A total of 38.2% of patients diagnosed with stage IV WT had 1q+ in their tumors, confirming the relatively high prevalence of 1q+ reported in other metastatic WT series [27, 31, 48, 50]. Previous analyses of unilateral WT patients of all stages found 1q+ in 28% and 19% of patients, respectively [27, 31], and the COG reported a prevalence of 28% of 1q+ in a large cohort of WT with favorable

histology (stage II–IV), rising to 44% if only stage IV is considered [46]. This suggests that 1q+ is more common in advanced WT stages, in line with observations from Hing et al. [43]. In our cohort, 1q+ occurred in 38.2% of patients and was associated with a significantly higher age at diagnosis than 1q other status (median age at diagnosis 65 months vs. 49 months). 1q+ had no impact on the TV at diagnosis ($p = 0.46$, Table 4).

For WT of all stages, SIOP-RSTG and COG reported significantly worse EFS for 1q+ [27, 31, 46]. The higher relapse risk was described earlier in independent patient cohorts from different

TABLE 3 | 1q gain and corresponding copy number variations.

		1q status		<i>p</i>
		Gain (<i>n</i> = 21)	Other (<i>n</i> = 34)	
		<i>n</i> (%)	<i>n</i> (%)	
1p status	Loss (<i>n</i> = 5)	3 (14.3)	2 (5.9)	0.36 ^a
	Other (<i>n</i> = 50)	18 (85.7)	32 (94.1)	
16q status	Loss (<i>n</i> = 8)	2 (9.5)	6 (17.6)	0.70 ^a
	Other (<i>n</i> = 47)	19 (90.5)	28 (82.4)	
1p16q status	Loss (<i>n</i> = 1)	0 (0.0)	1 (2.9)	>0.99 ^a
	Other (<i>n</i> = 54)	21 (100.0)	33 (97.1)	
MYCN status	Gain (<i>n</i> = 10)	7 (33.3)	3 (8.8)	0.03 ^a
	Other (<i>n</i> = 45)	14 (66.7)	31 (91.2)	
TP53 status	Loss (<i>n</i> = 9)	4 (19.0)	5 (14.7)	0.72
	Other (<i>n</i> = 46)	17 (81.0)	29 (85.3)	
WT1 status	Loss (<i>n</i> = 2)	1 (4.8)	1 (2.9)	0.73 ^a
	Other (<i>n</i> = 53)	20 (95.2)	33 (97.1)	
WTX status	Loss (<i>n</i> = 1)	1 (4.8)	0 (0.0)	0.38 ^a
	Normal (<i>n</i> = 54)	20 (95.2)	34 (100.0)	
Overall CNV status ^c	Variation (<i>n</i> = 26)	14 (66.7)	12 (35.3)	0.03 ^b
	Neutral (<i>n</i> = 29)	7 (33.3)	22 (64.7)	

Note: "Other" includes copy number variation (CNV) normal status, and gains or losses dependent on the respective variable.

^aFisher's exact test.

^bChi-square test.

^cAll CNVs of the left column included.

research groups, and seems particularly important in stage IV patients [40, 43, 46, 48, 51, 52].

Given this negative prognostic potential, we analyzed our data for a correlation of 1q+ with established prognostic factors such as histology, TV, and remission status of metastasis at the time of surgery [3, 7, 21]. In tumors with 1q+, a nonsignificant higher proportion of HR histology was observed, which is in line with the described association of 1q+ and HR blastemal subtype after pCHT [27, 53].

The COG reported for patients with only pulmonary metastasis and favorable histology, a remission rate after 6 weeks of CHT of 33.3% when 1q+ was present, compared to 50.3% for 1q other status [47]. In our series, 1q+ did not affect the remission rate of metastasis after pCHT ± metastasectomy, and TVs pre-nephrectomy did not differ from tumors with 1q other status. Patients with pulmonary-only metastasis had significant inferior EFS and OS if they were not in metastatic CR after pCHT ± metastasectomy and 1q+ was present in their tumors. For patients achieving CR after pCHT, no significant differences in EFS and OS were found depending on 1q status (Figure 2). This is in contrast with the results from the COG that reported for patients with 1q+ and pulmonary-only metastasis having achieved CR after 6 weeks of chemotherapy, a significantly worse EFS and trend toward inferior OS, but this was interestingly not observed in patients with non-CR [47]. This was explained by the omission

of pulmonary RT in the subclass of patients with CR. In our small series, administration of pRT in patients with pulmonary-only metastasis and 1q+ did not significantly improve 5-year EFS or OS (only 15 patients with available data, of whom only three received pRT). However, it must be considered that our cohort included patients with HR histology composed of DA only, whereas the COG cohort only comprised patients with favorable histology. Additionally, pulmonary CR was defined differently. In our cohort, it could be achieved by either pCHT or metastasectomy, whereas in the COG cohort, CR by chemotherapy only was required. Nevertheless, in summary, our results together with those of the COG emphasize the negative prognostic impact of 1q+ and suggest a potential benefit of treatment intensification.

As current protocols only consider treatment intensification in case of HR histology or preoperative non-CR, the question arises whether IR patients with 1q+ WT should also benefit from postoperative treatment intensification (including RT to the metastatic sites). This needs to be determined in further prospective clinical studies.

Concurrent MYCN gain was found in a significant higher proportion in tumors with 1q+. The relation between 1q+ and simultaneous loss of 1p and 16q could not be assessed in our series due to small numbers (Table 3). However, in general, additional CNVs were significantly more frequent in tumors with 1q+ than in tumors with 1q other status, suggesting a more

TABLE 4 | Clinical impact of 1q gain and TP53 loss.

	1q status			TP53 status			1q and/or TP53 status		
	1q+	Other	p	Loss	Other	p	1q+ and/or TP53 loss	Other	p
Frequency, n (%)	21 (38.2)	34 (61.8)		9 (16.4)	46 (83.6)		26 (47.3)	29 (52.7)	
Age [months]									
Median (IQR)	65 (42–75)	49 (28–60)	0.03	64 (57–109)	49 (34–65)	0.02	64 (45–82)	47 (27–60)	0.02
Sex, n (%)									
Females	12 (57.1)	15 (44.1)	0.35	7 (77.8)	20 (43.5)	0.08	16 (61.5)	11 (37.9)	0.08
Males	9 (42.9)	19 (55.9)		2 (22.2)	26 (56.5)		10 (38.5)	18 (62.1)	
TV at diagnosis [mL]									
Median (IQR)	612 (306–1074)	734 (535–962)	0.46	667 (420–940)	727 (494–1074)	0.73	747 (323–1085)	703 (520–960)	0.99
TV at surgery [mL]									
Median (IQR)	180 (60–373)	165 (81–380)	0.69	218 (168–929)	161 (55–340)	0.10	189 (87–442)	151 (59–347)	0.33
TV reduction [%]									
Median (IQR)	70 (54–80)	80 (63–89)	0.25	54 (8–82)	78 (59–89)	0.06	75 (44–80)	83 (64–90)	0.15
Abdominal stage, n (%)									
I	2 (9.5)	12 (35.3)	0.11	0 (0.0)	13 (28.8)	0.08	2 (7.7)	11 (37.9)	0.01
II	5 (23.8)	6 (17.6)		1 (11.1)	11 (23.9)		5 (19.2)	7 (24.1)	
III	14 (66.7)	16 (47.1)		8 (88.9)	22 (47.8)		19 (73.1)	11 (37.9)	
Histological subtype, n (%)									
IR	16 (76.2)	28 (82.4)	0.73	2 (22.2)	42 (91.3)	<0.01	17 (65.4)	27 (93.1)	0.01
HR	5 (23.8)	6 (17.6)		7 (77.8)	4 (8.7)		9 (34.6)	2 (6.9)	
Remission status after chemotherapy and surgery, n (%)									
CR	11 (52.4)	13 (41.9)	0.57	2 (22.2)	22 (51.2)	0.15	12 (46.2)	12 (46.2)	1.00
Non-CR	10 (47.6)	18 (58.1)		7 (77.8)	21 (48.8)		14 (53.8)	14 (53.8)	
NA		3			3			3	
Survival function									
5-year EFS (%)	42.9	70.6	0.04	11.1	69.6	<0.01	37.0	82.1	<0.01
5-year OS (%)	61.0	79.4	0.19	22.2	82.4	<0.01	51.2	92.9	<0.01

Abbreviations: CR, complete remission; EFS, event-free survival; HR, high risk; IR, intermediate risk; NA, not available; OS, overall survival; TV, tumor volume.

unstable genome when 1q+ is present. Similar observations are described for TP53 loss [28, 54].

TP53 loss was less common than 1q+ but still occurring in 16.4% of this stage IV cohort. Interestingly, females were more frequently affected (seven out of nine patients, Table 4). Like 1q+, TP53 loss correlated with a significant older age at diagnosis, which has been related to an unfavorable outcome in previous studies [24, 25].

We confirm the strong but not exclusive association of TP53 loss with HR histology [36, 41]. Our series of stage IV tumors with TP53 loss showed a very poor outcome, with a 5-year EFS and OS of only 11.1% and 22.2%, respectively, which is consistent with COG data reporting a particularly poor outcome of patients with stage IV WT, if TP53 was not wild-type [42].

When assessing the local extent of disease at diagnosis and the response to pCHT, we found no difference in initial TV, but a trend toward less TV reduction in response to pCHT and higher local tumor stages at surgery in tumors with TP53 loss compared to TP53 other status (Table 4). Both are described to correlate with poorer outcome [7, 32, 41].

Regarding metastasis, a higher proportion of metastatic non-CR was observed after pCHT in patients having tumors with TP53 loss (seven out of nine, 77.8%) compared to 48.8% with TP53 other status (Tables 2 and 4). The association between TP53 loss and other negative prognostic factors (higher local stage, less preoperative volume reduction, higher rate of non-CR) needs to be further investigated in larger and more representative series in the future. If our results are confirmed, this will emphasize the clinical need of molecular diagnostics to determine, for example, TP53 status at the time of diagnosis. According to SIOP protocols,




FIGURE 2 | Outcome of patients with pulmonary-only metastasis according to remission status after pCMT ± metastatectomy and presence of 1q+.

histology at diagnosis is often not available, and the development of liquid biopsies detecting circulating tumor DNA could be helpful as a diagnostic tool. By using this in the future, treatment could be adapted earlier in specific cases. It has already been shown that the detection of *TP53*-mutated WT in circulating DNA in the patient's blood is possible using a droplet digital polymerase chain reaction [55].

In the current SIOP-RTSG-2016 UMBRELLA protocol, liquid biopsies are performed within a research setting at well-defined time points. In a pilot series, the determination of molecular tumor markers appears to be possible using liquid biopsies [56–59].

MYCN gain, which was associated with adverse outcome in previous WT series [29], was the second most prevalent CNV (18.2%

of tumors) in our series. It has been identified as corresponding CNV to 1q+ ($p = 0.03$) and patients with *MYCN* gain had a nearly significant inferior EFS ($p = 0.09$) (Tables 1 and 3, Figure 1). Regarding the prevalence of 1p and 16q loss, our results (9.1% and 14.5% of patients, respectively, in our series) are consistent with literature [32]. No difference in frequency was seen in our stage IV patients compared to localized stages [27]. Only one patient (1.8%) had simultaneous loss of 1p and 16q.

Our study has some limitations. A selection bias is likely as only 55 of 373 stage IV patients had sufficiently complete data to be included in the analysis, and only patients from three European countries were selected. The extent to which our cohort is representative of the overall stage IV cohort cannot be accurately assessed and must be investigated in prospective studies. Particularly, the distribution of risk groups of 80% IR

versus 20% HR (all DA) is biased and contributes to a worse outcome of our patient cohort. In addition, our results are based on a small number of patients. Since in SIOP 2001 study, consent for biological studies was not defined as an inclusion criterion no standardized biomarker sampling was performed across all participating countries. Furthermore, not all relevant molecular changes can be determined with copy number analysis. In *TP53* and *MYCN*, single nucleotide variants have a considerable influence on the biology in WT. In case of *MYCN*, P44L point mutation is particularly noteworthy, but it is still not as frequent as *MYCN* gain (e.g., 4.1% vs. 11.5% in Gadd et al., 2017). Thus, our data cover at least a major share of *MYCN* alterations. Similarly, *TP53* point mutations that we did not score here, are often combined with the loss of the second allele, which is detectable by MLPA. This was the case in 91% and 82% of *TP53* mutant cases reported by Maschietto et al. and Ooms et al., respectively [29, 42, 60]. Our results are based on a single tumor sampling. However, intratumoral heterogeneity was described for 1q+ in particular, suggesting that not all 1q+ tumors may have been detected in our study [54, 61]. In UMBRELLA, systematic multisampling of blood as well as fresh frozen and viable tumor tissue at protocol-defined time points will be performed to obtain more representative results [62].

In conclusion, our analysis confirms the prognostic significance of 1q+ and *TP53* loss for the specific subgroup of preoperatively treated patients with stage IV WT, which was previously shown for the overall WT cohort of SIOP 2001 by Chagtai et al. In particular, our results underline their potential benefit for future treatment stratification in the stage IV subgroup. Considering the proportion of 76% IR histology in patients with stage IV and 1q+ and their significantly inferior EFS compared to patients without 1q+, the question arises of whether further intensification of postoperative therapy for patients with IR stage IV WT presenting 1q+ is necessary in future studies. The prognostic value of 1q+ for the stage IV subgroup is underlined by significantly worse 5-year EFS and OS of patients with pulmonary-only metastases in non-CR after pCHT and surgery when 1q+ was present. SIOP-RTSG-2016 UMBRELLA and SIOP Randomet 2017 will provide further insights on the prognostic impact of CNVs.

Acknowledgments

The authors thank all patients and their families for participating in the SIOP 2001 study and for consenting to the collection and storage of biomaterial. The authors also thank the treatment centers in France, Germany, and the United Kingdom for collecting, storing, and sending the tumor tissue to the national biobanks. The following grants and associations financed the SIOP study 2001 in the respective countries: The Société Française des Cancers de l'Enfant and Association Leon Berard Enfant Cancéreux and Fédération Enfants Cancers Santé, the Gesellschaft für Pädiatrische Onkologie und Hämatologie and Deutsche Krebshilfe (grant 50-2709-Gr) for Germany, and the Cancer Research UK (grant C1188/A8687), the UK National Cancer Research Network, and Children's Cancer and Leukaemia Group (CCLG) for the United Kingdom.

Open access funding enabled and organized by Projekt DEAL.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. K. Nakata, M. Colombet, C. A. Stiller, K. Pritchard-Jones, and E. Steliarova-Foucher, "Incidence of Childhood Renal Tumours: An International Population-Based Study," *International Journal of Cancer* 147, no. 12 (2020): 3313–3327, <https://doi.org/10.1002/ijc.33147>.
2. G. Pastore, A. Znaor, F. Spreafico, et al., "Malignant Renal Tumours Incidence and Survival in European Children (1978–1997): Report from the Automated Childhood Cancer Information System Project," *European Journal of Cancer* 2006;42(13):2103–2114, <https://doi.org/10.1016/j.ejca.2006.05.010>.
3. A. Verschuur, H. Van Tinteren, N. Graf, C. Bergeron, B. Sandstedt, and J. De Kraker, "Treatment of Pulmonary Metastases in Children with Stage IV Nephroblastoma with Risk-Based Use of Pulmonary Radiotherapy," *Journal of Clinical Oncology* 30, no. 28 (2012): 3533–3539, <https://doi.org/10.1200/JCO.2011.35.8747>.
4. M. Berger, I. Fernandez-Pineda, R. Cabello, et al., "The Relationship Between the Site of Metastases and Outcome in Children with Stage IV Wilms Tumor: Data from 3 European Pediatric Cancer Institutions," *Journal of Pediatric Hematology/Oncology* 35 (2013): 518–524.
5. M. M. van den Heuvel-Eibrink, J. A. Hol, K. Pritchard-Jones, et al., "Position Paper: Rationale for the Treatment of Wilms Tumour in the UMBRELLA SIOP-RTSG 2016 Protocol," *Nature Reviews Urology* 14, no. 12 (2017): 743–752, <https://doi.org/10.1038/nrurol.2017.163>.
6. C. Pasqualini, R. Furtwängler, H. van Tinteren, et al., "Outcome of Patients with Stage IV High-Risk Wilms Tumour Treated According to the SIOP2001 Protocol: A Report of the SIOP Renal Tumour Study Group," *European Journal of Cancer* 128 (2020): 38–46, <https://doi.org/10.1016/j.ejca.2020.01.001>.
7. J. C. de Aguirre-Neto, B. de Camargo, H. van Tinteren, et al., "International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study," *JCO Global Oncology* 8 (2022): e2100425, <https://doi.org/10.1200/go.21.00425>.
8. P. F. Ehrlich, F. A. Ferrer, M. L. Ritchey, et al., "Hepatic Metastasis at Diagnosis in Patients with Wilms Tumor Is Not an Independent Adverse Prognostic Factor for Stage IV Wilms Tumor: A Report from the Children's Oncology Group/National Wilms Tumor Study Group," *Annals of Surgery* 250, no. 4 (2009): 642–647, <https://doi.org/10.1097/SLA.0B013E3181B76F20>.
9. D. S. M. Iaboni, Y. Y. Chi, Y. Kim, J. S. Dome, and C. V. Fernandez, "Outcome of Wilms Tumor Patients with Bone Metastasis Enrolled on National Wilms Tumor Studies 1–5: A Report from the Children's Oncology Group," *Pediatric Blood & Cancer* 66, no. 1 (2019): e27430, <https://doi.org/10.1002/pbc.27430>.
10. K. Pritchard-Jones, V. Moroz, G. Vujanić, et al., "Treatment and Outcome of Wilms' Tumour Patients: An Analysis of all Cases Registered in the UKW3 Trial," *Annals of Oncology* 23, no. 9 (2012): 2457–2463, <https://doi.org/10.1093/annonc/mds025>.
11. F. Spreafico, C. V. Fernandez, J. Brok, et al., "Wilms Tumour," *Nature Reviews Disease Primers* 7, no. 1 (2021): 75, <https://doi.org/10.1038/s41572-021-00308-8>.
12. J. Brok, K. Pritchard-Jones, J. I. Geller, and F. Spreafico, "Review of Phase I and II Trials for Wilms' tumour—Can We Optimise the Search for Novel Agents?," *European Journal of Cancer* 79 (2017): 205–213, <https://doi.org/10.1016/j.ejca.2017.04.005>.
13. M. V. Nelson, M. M. van den Heuvel-Eibrink, N. Graf, and J. S. Dome, "New Approaches to Risk Stratification for Wilms Tumor," *Current Opinion in Pediatrics* 33, no. 1 (2021): 40–48, <https://doi.org/10.1097/MOP.0000000000000988>.

14. M. V. Ortiz, C. Koenig, A. E. Armstrong, et al., "Advances in the Clinical Management of High-Risk Wilms Tumors," *Pediatric Blood & Cancer* 70, no. 3 (2023): e30153, <https://doi.org/10.1002/pbc.30153>.
15. H. Reinhard, A. Schmidt, R. Furtwängler, et al., "Outcome of Relapses of Nephroblastoma in Patients Registered in the SIOP/GPOH Trials and Studies," *Oncology Reports* 20, no. 2 (2008): 463–467, https://doi.org/10.3892/or_00000029.
16. A. Groenendijk, H. van Tinteren, Y. Jiang, et al., "Outcome of SIOP Patients with Low- or Intermediate-Risk Wilms Tumour Relapsing After Initial Vincristine and Actinomycin-D Therapy Only—The SIOP 93-01 and 2001 Protocols," *European Journal of Cancer* 163 (2022): 88–97, <https://doi.org/10.1016/j.ejca.2021.12.014>.
17. S. W. Warmann, R. Furtwängler, G. Blumenstock, et al., "Tumor Biology Influences the Prognosis of Nephroblastoma Patients with Primary Pulmonary Metastases: Results from SIOP 93-01/GPOH and SIOP 2001/GPOH," *Annals of Surgery* 254, no. 1 (2011): 155–162, <https://doi.org/10.1097/SLA.0b013e318222015e>.
18. J. Brok, T. D. Treger, S. L. Gooskens, M. M. van den Heuvel-Eibrink, and K. Pritchard-Jones, "Biology and Treatment of Renal Tumours in Childhood," *European Journal of Cancer* 68 (2016): 179–195, <https://doi.org/10.1016/j.ejca.2016.09.005>.
19. N. Graf, C. Bergeron, J. Brok, et al., "Fifty Years of Clinical and Research Studies for Childhood Renal Tumors within the International Society of Pediatric Oncology (SIOP)," *Annals of Oncology* 32, no. 11 (2021): 1327–1331, <https://doi.org/10.1016/j.annonc.2021.08.1749>.
20. A. M. Davidoff, "Wilms Tumor," *Advances in Pediatrics* 59, no. 1 (2012): 247–267, <https://doi.org/10.1016/j.yapd.2012.04.001>.
21. J. De Kraker, J. Lemerle, P. Voûte, J. Zucker, M. Tournade, and M. Carli, "Wilm's Tumor with Pulmonary Metastases at Diagnosis: The Significance of Primary Chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee," *Journal of Clinical Oncology* 8, no. 7 (1990): 1187–1190, <https://doi.org/10.1200/JCO.1990.8.7.1187>.
22. K. Pritchard-Jones, A. Kelsey, G. Vujanic, J. Imeson, C. Hutton, and C. Mitchell, "Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms' Tumor Treated with Vincristine Monochemotherapy: A Study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group," *Journal of Clinical Oncology* 21, no. 17 (2003): 3269–3275, <https://doi.org/10.1200/JCO.2003.01.062>.
23. J. S. Dome, N. Graf, J. I. Geller, et al., "Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration," *Journal of Clinical Oncology* 33, no. 27 (2015): 2999–3007, <https://doi.org/10.1200/JCO.2015.62.1888>.
24. S. L. Gooskens, H. Segers, K. Pritchard-Jones, N. Graf, J. S. Dome, and M. M. van den Heuvel-Eibrink, "The Clinical Relevance of Age at Presentation in Nephroblastoma," in *Wilms Tumor* (Codon Publications, 2016), 23–30, <https://doi.org/10.15586/codon.wt.2016.ch2>.
25. J. A. Hol, M. I. Lopez-Yurda, H. Van Tinteren, et al., "Prognostic Significance of Age in 5631 Patients with Wilms Tumour Prospectively Registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001," *PLOS One* 14, no. 8 (2019): e0221373, <https://doi.org/10.1371/journal.pone.0221373>.
26. A. Groenendijk, F. Spreafico, R. R. De Krijger, et al., "Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature," *Cancers* 13, no. 13 (2021): 3142, <https://doi.org/10.3390/cancers13133142>.
27. T. Chagtai, C. Zill, L. Dainese, et al., "Gain of 1q as a Prognostic Biomarker in Wilms Tumors (WTs) Treated with Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study," *Journal of Clinical Oncology* 34, no. 26 (2016): 3195–3203, <https://doi.org/10.1200/JCO.2015.66.0001>.
28. M. Maschietto, R. D. Williams, T. Chagtai, et al., "TP53 Mutational Status is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia," *PLOS One* 9, no. 10 (2014): e109924, <https://doi.org/10.1371/journal.pone.0109924>.
29. R. D. Williams, T. Chagtai, M. Alcaide-German, et al., "Multiple Mechanisms of MYCN Dysregulation in Wilms Tumour," *Oncotarget* 6, no. 9 (2015): 7232–7243, <https://doi.org/10.18632/oncotarget.3377>.
30. F. Spreafico, B. Gamba, L. Mariani, et al., "Loss of Heterozygosity Analysis at Different Chromosome Regions in Wilms Tumor Confirms 1p Allelic Loss as a Marker of Worse Prognosis: A Study from the Italian Association of Pediatric Hematology and Oncology," *Journal of Urology* 189, no. 1 (2013): 260–267, <https://doi.org/10.1016/j.juro.2012.09.009>.
31. H. Segers, M. M. van den Heuvel-Eibrink, R. D. Williams, et al., "Gain of 1q is a Marker of Poor Prognosis in Wilms' Tumors," *Genes, Chromosomes & Cancer* 52, no. 11 (2013): 1065–1074, <https://doi.org/10.1002/gcc.22101>.
32. B. Messahel, R. Williams, A. Ridolfi, et al., "Allele Loss at 16q Defines Poorer Prognosis Wilms Tumour Irrespective of Treatment Approach in the UKW1-3 Clinical Trials: A Children's Cancer and Leukaemia Group (CCLG) Study," *European Journal of Cancer* 45, no. 5 (2009): 819–826, <https://doi.org/10.1016/j.ejca.2009.01.005>.
33. J. Wegert, N. Ishaque, R. Vardapour, et al., "Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors," *Cancer Cell* 27, no. 2 (2015): 298–311, <https://doi.org/10.1016/j.ccell.2015.01.002>.
34. A. L. Walz, A. Ooms, S. Gadd, et al., "Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors," *Cancer Cell* 27, no. 2 (2015): 286–297, <https://doi.org/10.1016/J.CCELL.2015.01.003>.
35. S. Gadd, V. Huff, A. L. Walz, et al., "A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor," *Nature Genetics* 49, no. 10 (2017): 1487–1494, <https://doi.org/10.1038/ng.3940>.
36. T. D. Treger, T. Chowdhury, K. Pritchard-Jones, and S. Behjati, "The Genetic Changes of Wilms Tumour," *Nature Reviews Nephrology* 15, no. 4 (2019): 240–251, <https://doi.org/10.1038/s41581-019-0112-0>.
37. A. Smets, H. Van Tinteren, C. Bergeron, et al., "The Contribution of Chest CT-Scan at Diagnosis in Children with Unilateral Wilms' Tumour. Results of the SIOP 2001 Study," *European Journal of Cancer* 48, no. 7 (2012): 1060–1065, <https://doi.org/10.1016/j.ejca.2011.05.025>.
38. P. Grundy, E. Perlman, N. S. Rosen, et al., "Current Issues in Wilms Tumor Management," *Current Problems in Cancer* 29, no. 5 (2005): 223–260, <https://doi.org/10.1016/j.currprobcancer.2005.08.002>.
39. G. M. Vujanic and B. Sandstedt, "The Pathology of Wilms' Tumour (Nephroblastoma): The International Society of Paediatric Oncology Approach," *Journal of Clinical Pathology* 63, no. 2 (2010): 102–109, <https://doi.org/10.1136/JCP.2009.064600>.
40. Y. J. Lu, S. Hing, R. Williams, R. Pinkerton, J. Shipley, and K. Pritchard-Jones, "Chromosome 1q Expression Profiling and Relapse in Wilms' Tumour," *Lancet* 360, no. 9330 (2002): 385–386, [https://doi.org/10.1016/S0140-6736\(02\)09596-X](https://doi.org/10.1016/S0140-6736(02)09596-X).
41. J. Wegert, C. Vokuhl, B. Ziegler, et al., "TP53 alterations in Wilms Tumour Represent Progression Events with Strong Intratumour Heterogeneity That are Closely Linked but Not Limited to Anaplasia," *Journal of Pathology: Clinical Research* 3, no. 4 (2017): 234–248, <https://doi.org/10.1002/cjp2.77>.
42. A. Ooms, S. Gadd, D. S. Gerhard, et al., "Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group," *Clinical Cancer Research* 22, no. 22 (2016): 5582–5591, <https://doi.org/10.1158/1078-0432.CCR-16-0985>.
43. S. Hing, Y. J. Lu, B. Summersgill, et al., "Gain of 1q Is Associated with Adverse Outcome in Favorable Histology Wilms' Tumors," *American Journal of Pathology* 158, no. 2 (2001): 393–398, [https://doi.org/10.1016/S0002-9440\(10\)63982-X](https://doi.org/10.1016/S0002-9440(10)63982-X).

44. P. E. Grundy, N. E. Breslow, S. Li, et al., "Loss of Heterozygosity for Chromosomes 1p and 16q is an Adverse Prognostic Factor in Favorable-histology Wilms Tumor: A Report from the National Wilms Tumor Study Group," *Journal of Clinical Oncology* 23, no. 29 (2005): 7312–7321, <https://doi.org/10.1200/JCO.2005.01.2799>.
45. J. S. Dome, E. J. Perlman, and N. Graf, "Risk Stratification for Wilms Tumor: Current Approach and Future Directions," *American Society of Clinical Oncology Educational Book* 34 (2014): 215–223, https://doi.org/10.14694/edbook_am.2014.34.215.
46. E. J. Gratiyas, J. S. Dome, L. J. Jennings, et al., "Association of Chromosome 1q Gain with Inferior Survival in Favorable-histology Wilms Tumor: A Report from the Children's Oncology Group," *Journal of Clinical Oncology* 34, no. 26 (2016): 3189–3194, <https://doi.org/10.1200/JCO.2015.66.1140>.
47. D. B. Dix, N. L. Seibel, Y. Y. Chi, et al., "Treatment of Stage IV Favorable Histology Wilms Tumor with Lung Metastases: A Report from the Children's Oncology Group AREN0533 Study," *Journal of Clinical Oncology* 36, no. 16 (2018): 1564–1570, <https://doi.org/10.1200/JCO.2017.77.1931>.
48. E. J. Gratiyas, L. J. Jennings, J. R. Anderson, J. S. Dome, P. Grundy, and E. J. Perlman, "Gain of 1q is Associated with Inferior Event-Free and Overall Survival in Patients with Favorable Histology Wilms Tumor: A Report from the Children's Oncology Group," *Cancer* 119, no. 21 (2013): 3887–3894, <https://doi.org/10.1002/cncr.28239>.
49. D. Doganis, A. Zborovskaya, M. Trojanowski, et al., "Wilms Tumour Event-Free and Overall Survival in Southern and Eastern Europe: Pooled Analyses of Clinical Data from Four Childhood Cancer Registries (1999–2017)," *European Journal of Cancer* 115 (2019): 37–46, <https://doi.org/10.1016/j.ejca.2019.04.008>.
50. N. Bown, S. J. Cotterill, P. Roberts, et al., "Cytogenetic Abnormalities and Clinical Outcome in Wilms," *Medical and Pediatric Oncology* 38, no. 1 (2002): 11–21, <https://doi.org/10.1002/mpo.1258>.
51. R. Natrajan, R. D. Williams, S. N. Hing, et al., "Array CGH Profiling of Favourable Histology Wilms Tumours Reveals Novel Gains and Losses Associated with Relapse," *Journal of Pathology* 210, no. 1 (2006): 49–58, <https://doi.org/10.1002/path.2021>.
52. D. Perotti, F. Spreafico, F. Torri, et al., "Genomic Profiling by Whole-Genome Single Nucleotide Polymorphism Arrays in Wilms Tumor and Association with Relapse," *Genes, Chromosomes & Cancer* 51, no. 7 (2012): 644–653, <https://doi.org/10.1002/gcc.21951>.
53. M. M. van den Heuvel-Eibrink, H. van Tinteren, C. Bergeron, et al., "Outcome of Localised Blastemal-Type Wilms Tumour Patients Treated According to Intensified Treatment in the SIOP WT 2001 Protocol, a Report of the SIOP Renal Tumour Study Group (SIOP-RTSG)," *European Journal of Cancer* 51, no. 4 (2015): 498–506, <https://doi.org/10.1016/j.ejca.2014.12.011>.
54. W. Mifsud and K. Pritchard-Jones, "Paediatrics: Integrating Genomics to Dig Deeper into Wilms Tumour Biology," *Nature Reviews Urology* 14, no. 12 (2017): 703–704, <https://doi.org/10.1038/nrurol.2017.178>.
55. T. D. Treger, T. Chagtai, R. Butcher, et al., "Somatic TP53 Mutations are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors," *Translational Oncology* 11, no. 6 (2018): 1301–1306, <https://doi.org/10.1016/j.tranon.2018.08.006>.
56. I. Jiménez, M. Chicard, L. Colmet-Daage, et al., "Circulating Tumor DNA Analysis Enables Molecular Characterization of Pediatric Renal Tumors at Diagnosis," *International Journal of Cancer* 144, no. 1 (2019): 68–79, <https://doi.org/10.1002/ijc.31620>.
57. A. L. Walz, M. Maschietto, B. Crompton, et al., "Tumor Biology, Biomarkers, and Liquid Biopsy in Pediatric Renal Tumors," *Pediatric Blood & Cancer* 70, no. S2 (2023): e30130, <https://doi.org/10.1002/pbc.30130>.
58. R. Van Paemel, C. Vandeputte, L. Raman, et al., "The Feasibility of Using Liquid Biopsies as a Complementary Assay for Copy Number Aberration Profiling in Routinely Collected Paediatric Cancer Patient Samples," *European Journal of Cancer* 160 (2022): 12–23, <https://doi.org/10.1016/J.EJCA.2021.09.022>.
59. L. M. J. van Zogchel, N. S. M. Lak, O. Verhagen, et al., "Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients with Pediatric Solid Tumors," *JCO Global Oncology* 5, no. 5 (2021): 1738–1748, <https://doi.org/10.1200/PO.21.00130>.
60. O. Jiménez Martín, A. Schlosser, R. Furtwängler, J. Wegert, and M. Gessler, "MYCN and MAX Alterations in Wilms Tumor and Identification of Novel N-MYC Interaction Partners as Biomarker Candidates," *Cancer Cell International* 21, no. 1 (2021): 555, <https://doi.org/10.1186/s12935-021-02259-2>.
61. G. D. Cresswell, J. R. Apps, T. Chagtai, et al., "Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications," *EBioMedicine* 9 (2016): 120–129, <https://doi.org/10.1016/j.ebiom.2016.05.029>.
62. G. M. Vujančić, M. Gessler, A. Ooms, et al., "The UMBRELLA SIOP-RTSG 2016 Wilms Tumour Pathology and Molecular Biology Protocol," *Nature Reviews Urology* 15, no. 11 (2018): 693–701, <https://doi.org/10.1038/s41585-018-0100-3>.